These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

529 related items for PubMed ID: 31954998

  • 1. Efficacy and safety of adjunctive perampanel in adolescent patients with epilepsy: Post hoc analysis of six randomized studies.
    Piña-Garza JE, Rosenfeld W, Saeki K, Villanueva V, Yoshinaga H, Patten A, Williams B, Malhotra M.
    Epilepsy Behav; 2020 Mar; 104(Pt A):106876. PubMed ID: 31954998
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of adjunctive perampanel 4 mg/d for the treatment of focal seizures: A pooled post hoc analysis of four randomized, double-blind, phase III studies.
    Steinhoff BJ, Patten A, Williams B, Malhotra M.
    Epilepsia; 2020 Feb; 61(2):278-286. PubMed ID: 31944276
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies.
    Steinhoff BJ, Ben-Menachem E, Ryvlin P, Shorvon S, Kramer L, Satlin A, Squillacote D, Yang H, Zhu J, Laurenza A.
    Epilepsia; 2013 Aug; 54(8):1481-9. PubMed ID: 23663001
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase III randomized trials: Study 307.
    Krauss GL, Perucca E, Kwan P, Ben-Menachem E, Wang XF, Shih JJ, Patten A, Yang H, Williams B, Laurenza A.
    Epilepsia; 2018 Apr; 59(4):866-876. PubMed ID: 29574701
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305.
    French JA, Krauss GL, Steinhoff BJ, Squillacote D, Yang H, Kumar D, Laurenza A.
    Epilepsia; 2013 Jan; 54(1):117-25. PubMed ID: 22905857
    [Abstract] [Full Text] [Related]

  • 11. Long-term effects of adjunctive perampanel on cognition in adolescents with partial seizures.
    Piña-Garza JE, Lagae L, Villanueva V, Renfroe JB, Laurenza A, Williams B, Kumar D, Meador KJ.
    Epilepsy Behav; 2018 Jun; 83():50-58. PubMed ID: 29653338
    [Abstract] [Full Text] [Related]

  • 12. Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial.
    Biton V, Berkovic SF, Abou-Khalil B, Sperling MR, Johnson ME, Lu S.
    Epilepsia; 2014 Jan; 55(1):57-66. PubMed ID: 24446953
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of perampanel in adolescent patients with drug-resistant partial seizures in three double-blind, placebo-controlled, phase III randomized clinical studies and a combined extension study.
    Rosenfeld W, Conry J, Lagae L, Rozentals G, Yang H, Fain R, Williams B, Kumar D, Zhu J, Laurenza A.
    Eur J Paediatr Neurol; 2015 Jul; 19(4):435-45. PubMed ID: 25823975
    [Abstract] [Full Text] [Related]

  • 14. Time to prerandomization monthly seizure count in perampanel trials: A novel epilepsy endpoint.
    French JA, Gil-Nagel A, Malerba S, Kramer L, Kumar D, Bagiella E.
    Neurology; 2015 May 19; 84(20):2014-20. PubMed ID: 25878175
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of perampanel in patients with drug-resistant partial seizures after conversion from double-blind placebo to open-label perampanel.
    Montouris G, Yang H, Williams B, Zhou S, Laurenza A, Fain R.
    Epilepsy Res; 2015 Aug 19; 114():131-40. PubMed ID: 26088896
    [Abstract] [Full Text] [Related]

  • 16. Sustained seizure freedom with adjunctive perampanel in patients with convulsive seizures: Post hoc analysis of open-label extension studies 307 and 332.
    Resnick T, Patten A, Ngo LY, Malhotra M.
    Epilepsy Behav; 2022 Mar 19; 128():108528. PubMed ID: 35078116
    [Abstract] [Full Text] [Related]

  • 17. Adjunctive perampanel in adolescents with inadequately controlled partial-onset seizures: A randomized study evaluating behavior, efficacy, and safety.
    Lagae L, Villanueva V, Meador KJ, Bagul M, Laurenza A, Kumar D, Yang H.
    Epilepsia; 2016 Jul 19; 57(7):1120-9. PubMed ID: 27221398
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Safety and efficacy of perampanel in children and adults with various epilepsy syndromes: A single-center postmarketing study.
    Singh K, Shah YD, Luciano D, Friedman D, Devinsky O, Kothare SV.
    Epilepsy Behav; 2016 Aug 19; 61():41-45. PubMed ID: 27300147
    [Abstract] [Full Text] [Related]

  • 20. Adjunctive perampanel in partial-onset seizures: Asia-Pacific, randomized phase III study.
    Nishida T, Lee SK, Inoue Y, Saeki K, Ishikawa K, Kaneko S.
    Acta Neurol Scand; 2018 Apr 19; 137(4):392-399. PubMed ID: 29250772
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.